Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 55218

Manuscript Type: REVIEW

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer

Navid Sobhani, Marianna Sirico, Daniele Generali, Fabrizio Zanconati, Bruna Scaggiante

Abstract

Metastatic castrate-resistant prostate cancer (mCRPC), remains a disease hard to cure, for this reason predictive tools to monitor disease progression and therapy response are an urgent need. In this respect, liquid biopsy on circulating cell-free nucleic acids represents an interesting strategy based on robust data. The poor invasiveness and the possibility to target circulating cell-

国内版 国际版

Circulating cell-free nucleic acids as prognostic and thera

ALL IMAGES VIDEOS

26,900 Results Any time

Circulating nucleic acids as biomarkers of prostate cancer

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435153

CAPRA: Cancer of the Prostate Risk Assessment; CTC: **Circulating tumor cell**; HRPC: Hormone-refractory prostate cancer; PC: **Prostate cancer**. miRNAs as **predictive biomarkers Predictive markers** are defined as those that can be used to **predict** a patient's response to a given **drug** or **therapy**, and thus can be used to stratify patients for **treatment**.

Cited by: 16 **Author:** Ailsa Sita-Lumsden, Claire E. Fletcher, D...
Publish Year: 2013

Cell-free nucleic acids as biomarkers in cancer patients ...

https://www.nature.com/articles/nrc3066

May 12, 2011 · **DNA**, **mRNA** and **microRNA** are released and **circulate** in the **blood of cancer patients**. This Review discusses the potential **clinical utility of cell-free nucleic acids** as **blood biomarkers**.

Cited by: 2193 **Author:** Heidi Schwarzenbach, Dave S. B. Hoon, ...
Publish Year: 2011

Circulating Nucleic Acids as Prostate Cancer Biomarkers ...

https://www.sciencedirect.com/science/article/pii/B9780128018996000280

Prostate cancer (PCa) is a growing clinical problem. Diagnosis rates are increasing but it lacks accurate biomarkers to distinguish between indolent and aggressive disease, to stratify patients for the rising numbers of treatment options, or to reliably predict relapse.

Author: Claire E. Fletcher, Ailsa Sita-Lumsden... **Publish Year:** 2016

Search Tools

Turn off Hover Trans

Circulating cell-free nucleic acids as prognostic and ther

ALL IMAGES VIDEOS MAPS NEWS SHOPPING

26,900 Results Any time

Circulating nucleic acids as biomarkers of prostate cancer

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435153

CAPRA: Cancer of the Prostate Risk Assessment; CTC: **Circulating tumor cell**; HRPC: Hormone-refractory prostate cancer; PC: **Prostate cancer**. miRNAs as **predictive biomarkers Predictive markers** are defined as those that can be used to **predict** a patient's response to a given **drug** or **therapy**, and thus can be used to stratify patients for **treatment**.

Cited by: 16 **Author:** Ailsa Sita-Lumsden, Claire E. Fletcher, D...
Publish Year: 2013

Cell-free nucleic acids as biomarkers in cancer patients ...

https://www.nature.com/articles/nrc3066

May 12, 2011 · Mehra, N. et al. **Circulating** mitochondrial **nucleic acids** have **prognostic** value for survival in patients with advanced **prostate cancer**. Clin. **Cancer** Res. 13 , 421–426 (2007).

Cited by: 2193 **Author:** Heidi Schwarzenbach, Dave S. B. Hoon, ...
Publish Year: 2011

Circulating cell-free nucleic acids: characteristics and ...

https://www.nature.com/articles/s41431-018-0132-4

Apr 23, 2018 · These samples contain cell-**free nucleic acids** (cfNAs) which are valuable markers in different diagnostic protocols like prenatal diagnosis of genetic diseases, detection of **cancer** and ...

Cited by: 21 **Author:** Ondrej Pös, Orsolya Biró, Tomas Szemes...
Publish Year: 2018

Circulating Tumor Cells in Prostate Cancer: From Discovery ...

https://academic.oup.com/clinchem/article/65/1/87/5607896

Jan 01, 2019 · **Prostate cancer** (PC) 3 represents the most common **cancer** type in men, amounting to approximately 400000 new cases each year in Europe alone (1, 2).The **prognosis** for an individual diagnosed with the disease varies across the clinical spectrum from localized to **metastatic**.

Cited by: 17 **Author:** Klaus Pantel, Claudia Hille, Howard I Scher
Publish Year: 2019